(Q43057295)

English

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients

scientific article published on 10 May 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

0 references

1 reference

based on heuristic

inferred from title

David Vermijlen

3

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Francesco Dieli

15

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Giuseppe Cicero

object named as

G Cicero

6

0 references

object named as

M Eberl

2

0 references

Giuliana Guggino

8

object named as

G Guggino

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

author name string

S Meraviglia

1

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

M Todaro

4

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

S Buccheri

5

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

C La Mendola

7

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

M D'Asaro

9

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

V Orlando

10

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

F Scarpa

11

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

A Roberts

12

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

N Caccamo

13

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

G Stassi

14

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

A C Hayday

16

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

publication date

10 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Clinical and Experimental Immunology

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

161

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

290-297

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2010.04167.X

21 January 2018

Engineering lymphocyte subsets: tools, trials and tribulations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Gammadelta T cells and the lymphoid stress-surveillance response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Breast cancer risk management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Perspectives of gammadelta T cells in tumor immunology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to V alpha 24+ NKT cell-mediated cytotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Adoptive immunotherapy for cancer: building on success

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Effector memory T cells, early metastasis, and survival in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Gamma delta T cells provide an early source of interferon gamma in tumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Microbial isoprenoid biosynthesis and human gammadelta T cell activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Gammadelta T cells for immune therapy of patients with lymphoid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Antigen recognition by human gamma delta T cells: pattern recognition by the adaptive immune system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Natural and synthetic non-peptide antigens recognized by human gamma delta T cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

30 September 2018

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909411

1 December 2018

FDA approves ZOMETA for treatment of cancer-related bone complications

1 reference

https://pubmed.ncbi.nlm.nih.gov/20491785

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands

1 reference

https://pubmed.ncbi.nlm.nih.gov/20491785

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential application of chemotherapy and monoclonal CD 20 antibody: successful treatment of advanced composite-lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20491785

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I

1 reference

https://pubmed.ncbi.nlm.nih.gov/20491785

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy and chemotherapy--a practical partnership

1 reference

https://pubmed.ncbi.nlm.nih.gov/20491785

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/20491785

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics

1 reference

https://pubmed.ncbi.nlm.nih.gov/20491785

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2249.2010.04167.X

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

release_7uzer2x3sjaxrcxrliknwc3it4

1 reference

https://api.fatcat.wiki/v0/release/7uzer2x3sjaxrcxrliknwc3it4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43057295&oldid=1979115885"